0001638599-17-001129.txt : 20171113 0001638599-17-001129.hdr.sgml : 20171110 20171113181912 ACCESSION NUMBER: 0001638599-17-001129 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171109 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SPRINGER TIMOTHY A CENTRAL INDEX KEY: 0001055624 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 171197644 MAIL ADDRESS: STREET 1: HARVARD MEDICAL SCHOOL, CTR CITY: BOSTON STATE: MA ZIP: 02115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SELECTA BIOSCIENCES INC CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4_5057.xml PRIMARY DOCUMENT X0306 4 2017-11-09 0 0001453687 SELECTA BIOSCIENCES INC SELB 0001055624 SPRINGER TIMOTHY A HARVARD MEDICAL SCHOOL, CTR 200 LONGWOOD AVE. BOSTON MA 02115 1 0 0 0 Common Stock 2017-11-09 4 P 0 21100 9.3314 A 376513 D Common Stock 2017-11-09 4 P 0 900 9.7407 A 377413 D Common Stock 2017-11-09 4 P 0 4900 9.3271 A 4900 I By wife Common Stock 2017-11-09 4 P 0 100 9.78 A 5000 I By wife Common Stock 2017-11-10 4 P 0 21586 9.0425 A 398999 D Common Stock 2017-11-10 4 P 0 4752 9.029 A 403751 D Common Stock 1237028 I See Footnote Common Stock 445576 I See Footnote The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.72 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.72 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.75 to $9.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Held by Leukon Investments LP ("Leukon"). Held by TAS Partners, LLC ("TAS"). /s/ David Abraham, Attorney-in-Fact for Timothy Springer 2017-11-13 EX-24 2 exhibit24.htm EXHIBIT 24 Exhibit 24

Exhibit 24

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Selecta Biosciences, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by Selecta Biosciences, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of June, 2016.

Signature: /s/ Timothy Springer

Print Name: Timothy Springer

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

David Abraham

John Leaman